Evelyn Partners Group Ltd’s Bristol-Myers Squibb BMY Stock Holding History

Evelyn Partners Group Ltd’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	+6,031	New	+$346K	﹤0.01%	235

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Evelyn Partners Group Ltd's BMY Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 6,031 shares worth $348K. The stake represents ﹤0.01% of the portfolio and ranks #235 among its holdings.

1,603 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Evelyn Partners Group Ltd held 6,031 shares of Bristol-Myers Squibb worth $348K as of Q2 2026.
Bristol-Myers Squibb was a new Evelyn Partners Group Ltd position in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #235 holding.
1,603 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.